BioCardia, Inc.
BioCardia, Inc. (Nasdaq Capital Market) is a clinical-stage biopharmaceutical company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's website is www.biocardia.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BioCardia, Inc. does
In the company’s own words
BioCardia, Inc. (Nasdaq Capital Market) is a clinical-stage biopharmaceutical company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's website is www.biocardia.com.
BioCardia operates two primary therapeutic platforms. The CardiAMP autologous mononuclear cell therapy platform targets ischemic heart failure with reduced ejection fraction and chronic myocardial ischemia through a mechanism of enhanced microvascular density and reduced fibrosis. This system comprises a cell potency screening test, point-of-care cell processing platform, and the proprietary Helix transendocardial biotherapeutic delivery system. The CardiALLO allogeneic mesenchymal stem cell therapy platform represents an off-the-shelf cell therapy designed for ischemic inflammatory heart failure and acute respiratory distress syndrome, leveraging immunomodulatory mechanisms of action.
The company's CardiAMP Cell Therapy System has completed three clinical trials for ischemic heart failure, including a Phase III pivotal study that demonstrated clinically meaningful improvements in quality of life and functional capacity, particularly in patients with elevated biomarkers of heart stress. The FDA granted Breakthrough Device Designation for CardiAMP in January 2022, representing the first cardiac cell therapy to receive this designation. BioCardia is exploring regulatory approval pathways with both the FDA and Japan's PMDA based on trial results.
The Helix delivery system enables minimally invasive catheter-based intramyocardial therapeutic delivery and serves as a therapeutic-enabling platform for BioCardia's own programs and selective partnerships with other developers of biotherapeutic interventions. The company also manufactures Morph steerable vascular access catheters, with FDA clearance for various vascular procedures.
BioCardia maintains manufacturing capabilities at its Sunnyvale, California facility for allogeneic cell production and device manufacturing. The company partners with Biomet Biologics for the CardiAMP autologous cell processing platform. BioCardia's intellectual property portfolio includes over seventy issued or pending U.S. and international patents covering cell therapies, biotherapeutic delivery systems, and vascular access products, with issued patents expiring between 2027 and 2040. The company targets a concentrated customer base of leading cardiologists at high-volume hospitals and medical centers for commercialization.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SUNNYVALE, CA
- Fiscal year end
- December
- CIK
- 925741
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BioCardia, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BioCardia, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BioCardia, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BioCardia, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BioCardia, Inc.'s last four quarterly filings that the numbers alone won't show?”